NCCID Disease Debriefs provide Canadian public health practitioners and clinicians with up-to-date reviews of essential information on prominent infectious diseases for Canadian public health practice. Information is gathered from key sources including the Public Health Agency of Canada (PHAC), the USA Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC).
This Disease Debrief provides quick links for public health and practitioner use.
***Une mise à jour des Points saillants sur COVID-19 est disponible en anglais (link). La mise à jour en français sera disponible d’ici 24 heures.
The Coronavirus disease (COVID-19) is a global pandemic as announced by the World Health Organization (WHO, March 11th, 2020). It is caused by SARS-COV-2 coronavirus, a virus strain never previously identified in humans. The genetic sequence indicates that it is a betacoronavirus, closely linked to the SARS virus. The government of Canada has issued COVID-19 pandemic guidance for the health sector for federal, provincial and territorial health authorities.
Government of Canada-Coronavirus disease (COVID-19)-For Health Professionals (English & French)
World Health Organization-Coronavirus disease (English & French)
Signs & symptoms
The most commonly observed symptoms of the Coronavirus disease (COVID-19) infection include fever, flu, fatigue, new or worsening cough, loss of appetite, loss of smell and/or taste, muscle and body ache, and headache. Gastrointestinal symptoms (abdominal pain, diarrhea, vomiting) can be less frequent. Shortness of breath is commonly reported in hospitalized patients.
The symptoms in the geriatric population and in people with underlying health conditions may be subtle or atypical e.g., they could present without fever or respiratory symptoms. This virus has an estimated incubation period from 1-14 days, with a median being 5-6 days, from exposure to symptom onset. Most individuals (97.5%) develop symptoms within 11.5 days of exposure. Recent research shows that transmission of the virus can occur from an infected person before they develop symptoms (pre-symptomatic transmission) and from an infected person who never develops symptoms (asymptomatic transmission).
Among children, most symptoms resemble those of adults (i.e. fever, cough, and shortness of breath); there may be gastrointestinal symptoms (diarrhea, abdominal pain, nausea, and vomiting) and skin rashes. A very rare complication associated with COVID-19 infection has been seen in children, severe multisystem inflammatory syndrome (MIS-C) which share features of typical or atypical Kawasaki disease or toxic shock syndrome.
|More frequent (>50%)||Less frequent (<50%)||Rare (<10%)|
|Fever 44-91%||Sputum production (28-33%)||Confusion|
|Cough (57-74%)||Muscle aches (11-44%)||Runny nose|
|Shortness of breath (31-63%)||Chest pain (16-36%)||Fainting|
|Fatigue (31-70%)||Diarrhea (5-24%)||Skin manifestations|
|Loss of appetite (39-84%)||Nausea/vomiting (5-19%)|
|Loss of smell and /or taste (54-88%)||Headache (6-70%)|
|Sore throat (11-13%)|
Government of Canada-Symptoms of COVID-19 (English & French)
Government of Canada-Signs-Symptoms and Severity of disease-A Clinical Guide (English & French)
World Health Organization-Coronavirus-Symptoms (English & French)
The main mode of transmission in the human-to-human spread of coronavirus disease is via respiratory droplets. Respiratory secretion from an infected person, through sneezing or coughing, reaches the mucous membrane of a healthy person causes the spread of the virus. However, transmission can also occur if a person touches an infected surface and then touches their eyes, mouth, or nose though the contribution of surfaces or objects in COVID-19 transmission is not completely understood.
The role of asymptomatic, pre-symptomatic and paucisymptomatic COVID-19 cases in the transmission is still under investigation. There is uncertainty regarding the period of infectiousness of a COVID-19 infected person but the evidence shows that an individual may be infectious for up to three days before presenting any symptoms. It has been reported that during the course of the infection, viral shedding may occur but the exact extent is unknown so far. The viral load remains the same for both children and adults suggesting that children can be as infectious as adults.
Government of Canada-Signs-Symptoms and Severity of Disease-A Clinical Guide (English & French)
Government of Canada – For Health professionals-Transmission (English & French)
World Health Organization – Novel Coronavirus (English & French)
Laboratory diagnostics and reporting
In Canada, the Public Health Agency of Canada’s National Microbiology Laboratory (NML) can identify COVID-19 and is the only place for conclusive diagnosis. In every province and territory, provincial and territorial public health labs (PHL) initiate testing and coordinates further testing with NML as required. Detailed protocols for microbiological investigations of severe acute respiratory infections are available. They serve as a reference for laboratory diagnosis and testing and specimen transport and shipment of this Novel Coronavirus.
The federal minister of health issued an interim order for the importation and sale of medical devices such as masks, respirators, eye protection, gowns, swabs, gloves, ventilators, and testing devices (nucleic acid-based testing and serology-based testing) for use in relation to COVID-19.
Government of Canada – Detecting and Reporting (English & French)
Government of Canada-Testing Devices for COVID-19-Overview (English & French)
National case definitions
To aid in early detection and containment and to characterize the clinical and epidemiologic features of COVID-19, Public Health of Canada established a national case definition. Surveillance case definitions are provided for standardized case classification and reporting to the Public Health Agency of Canada. They are based on the current level of epidemiological evidence, uncertainty, and public health response goals. They are subject to change as new information becomes available.
Please refer to the document below to obtain information for persons under investigation (PUI), probable and confirmed case definitions, and exposure criteria and mechanism of reporting:
Government of Canada – For Interim National Case Definition: Novel Coronavirus (2019-nCoV) (For Canada) (English & French)
For more information:
European Centre for Disease Prevention and Control-Case Definition and European Surveillance for COVID-19 (updated May 29, 2020) (English only)
Infection prevention and control
The Government of Canada published interim guidance for acute healthcare settings. The Public Health Agency of Canada (the Agency) develops infection prevention and control (IPC) guidelines to provide evidence-based recommendations to complement provincial/territorial public health efforts in monitoring, preventing, and controlling healthcare-associated infections. Please read in conjunction with relevant provincial, territorial, and local legislation, regulations, and policies.
Currently available scientific evidence and expert opinion informs guidance and is subject to change as new information on transmissibility and epidemiology becomes available.
There are currently no vaccines available to protect against human 2019 novel Coronavirus infection.
For more information outside of Canada
CDC – Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings (updated July 15, 2020) (English only)
Interim guidance for clinical management of patients with moderate to severe COVID-19
The government of Canada has issued interim guidance for clinical management of patients with moderate to severe COVID-19 with an endorsement from the Canadian Critical Care Society and Association of Medical Microbiology & Infectious Diseases on April 2, 2020.
Canada’s response and risks to Canadians
PHAC activated the Health Portfolio Operations Centre to support effective coordination of federal, provincial, and territorial preparedness and response to the emergence of COVID-19. PHAC has also published the F/P/T public health repose plan for biological events, which you can reference for more information.
Government of Canada – Coronavirus Disease (COVID-19): Canada’s Response (English & French)
Government of Canada – 2019 Novel Coronavirus: Prevention and Risks (English & French)
The government of Canada issued risk-informed decision-making guidelines for workplaces and businesses during the COVID-19 pandemic.
Vulnerable populations & COVID-19
Some Canadians are at higher risk of getting an infection and to develop severe complications associated with COVID-19 due to socio-economic and health status. The government of Canada has issued information on how organizations can support vulnerable populations during COVID-19. (English & French)
On March, 25th, 2020, the Canadian Pediatric Society issued current epidemiology and guidance for COVID-19 caused by SARS-COV-2 Virus, in children and on April, 20th, 2020 issued the acute management of pediatric coronavirus disease 2019 (COVID-19). (English & French)
Travel Advisory for Canadians
The Public Health Agency of Canada (PHAC) issued a Travel Health Notice level 3, outlining the potential dangers to Canadian travellers and the Canadian public. PHAC is recommending that Canadians should avoid all Non-essential travel outside of Canada. Self-isolation for 14 days is mandatory upon return from travel outside of Canada. Compliance with this order is subject to verification and enforcement. Those in violation may face transfer to a quarantine facility as well as fine or imprisonment. Any person experiencing fever, cough or difficulty in breathing, should continue to self-isolate and contact the local public health authority in their province or territory
Government of Canada-Coronavirus Disease (COVID-19): Travel advice (English & French)
Presently, “there are no drugs or vaccines authorized for COVID-19 treatment. However, Health Canada is closely monitoring all potential drugs and vaccines in the development phase in Canada and abroad by working with companies, academic research centres, and investigators to expedite the development and availability to Canadians”. According to Health Canada, in the case of hospitalized COVID-19 patients who require supplemental oxygen or mechanical ventilation, clinicians should strongly consider Intravenous Dexamethasone 6mg for 10 days (or until discharge if earlier) or equivalent glucocorticoid dose. Note: This guidance is not meant to replace clinical judgment or specialist consultation.